Symbols / ICU $2.48 +3.33%
ICU Chart
About
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 9.42M |
| Enterprise Value | -5.11M | Income | -13.66M | Sales | 881.00K |
| Book/sh | 3.36 | Cash/sh | 3.82 | Dividend Yield | — |
| Payout | 0.00% | Employees | 19 | IPO | — |
| P/E | — | Forward P/E | -0.96 | PEG | — |
| P/S | 10.70 | P/B | 0.74 | P/C | — |
| EV/EBITDA | — | EV/Sales | -5.80 | Quick Ratio | 3.44 |
| Current Ratio | 3.66 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -11.30 | EPS next Y | -2.57 | EPS Growth | — |
| Revenue Growth | 169.10% | Earnings | 2025-11-13 16:00 | ROA | -86.54% |
| ROE | -290.37% | ROIC | — | Gross Margin | 95.35% |
| Oper. Margin | -19.56% | Profit Margin | 0.00% | Shs Outstand | 3.80M |
| Shs Float | 3.56M | Short Float | 6.18% | Short Ratio | 2.64 |
| Short Interest | — | 52W High | 25.70 | 52W Low | 2.20 |
| Beta | -1.01 | Avg Volume | 111.04K | Volume | 27.48K |
| Target Price | $9.00 | Recom | None | Prev Close | $2.40 |
| Price | $2.48 | Change | 3.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.00
Mean price target
2. Current target
$2.48
Latest analyst target
3. DCF / Fair value
$-47.69
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.48
Low
$6.00
High
$12.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-04-20 | init | Maxim Group | — → Buy | $5 |
News
RSS: Latest ICU news- ICU Medical (NASDAQ: ICUI) CEO reports equity award vesting and tax share withholding - Stock Titan Mon, 16 Mar 2026 20
- Assessing ICU Medical (ICUI) Valuation After A Stretch Of Weak Share Price Returns - simplywall.st Sun, 15 Mar 2026 03
- ICU Medical, Inc. $ICUI Shares Purchased by Kennedy Capital Management LLC - MarketBeat Fri, 13 Mar 2026 14
- Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know - StockStory Fri, 06 Mar 2026 08
- ICU Medical Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo Fri, 13 Mar 2026 12
- ICU Medical (ICUI) CIO settles 1,300 RSUs; 718 shares withheld - Stock Titan Mon, 16 Mar 2026 20
- ICU Medical stock falls after SeaStar Medical trial enrollment increase - Investing.com hu, 25 Sep 2025 07
- Healthcare Stocks Review 2026: ICU Medical vs. Intuitive Surgical vs. Medpace - News and Statistics - IndexBox - Market Intelligence Platform Mon, 09 Mar 2026 09
- ICU Medical (ICUI) Shares Skyrocket, What You Need To Know - Yahoo Finance Fri, 07 Nov 2025 08
- Is ICU Medical (ICUI) Repricing Its Investment Story Amid Stagnant Revenue And Tighter Cash Margins? - simplywall.st Mon, 16 Mar 2026 21
- 50 children enrolled in FDA safety registry for sepsis kidney therapy - Stock Titan hu, 05 Mar 2026 08
- ICU Medical (ICUI) VP Woolson nets shares after PRSU awards, tax withholding - Stock Titan Mon, 09 Mar 2026 20
- ICU Medical Confronts Revenue Strain As Valuation Signals Potential Upside - simplywall.st Fri, 13 Mar 2026 20
- Why this medical company is turning 10 shares into 1 to stay on Nasdaq - Stock Titan ue, 23 Dec 2025 08
- ICU Medical (ICUI) COO settles PRSUs, withholds shares for taxes - Stock Titan Mon, 09 Mar 2026 20
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4200 | 987.0 | — | Purchase at price 0.24 per share. | BAIRD JENNIFER A | Director | — | 2025-12-19 00:00:00 | D |
| 1 | 14500 | 5098.0 | — | Purchase at price 0.35 per share. | MESSINGER MICHAEL | Chief Financial Officer | — | 2025-12-09 00:00:00 | D |
| 2 | 35000 | 30812.0 | — | Purchase at price 0.86 - 0.89 per share. | VAN HEEL KENNETH J. | Director | — | 2025-08-27 00:00:00 | D |
| 3 | 10000 | 8000.0 | — | Purchase at price 0.80 per share. | CHUNG KEVIN | Officer | — | 2025-08-22 00:00:00 | D |
| 4 | 4000 | nan | — | — | VAN HEEL KENNETH J. | Director | — | 2025-07-10 00:00:00 | D |
| 5 | 4000 | nan | — | — | NEUMAN JOHN | Director | — | 2025-07-10 00:00:00 | D |
| 6 | 4000 | nan | — | — | BAIRD JENNIFER A | Director | — | 2025-07-10 00:00:00 | D |
| 7 | 4000 | nan | — | — | VINCENT BERNADETTE N | Director | — | 2025-07-10 00:00:00 | D |
| 8 | 21667 | nan | — | — | SCHLORFF ERIC | Chief Executive Officer | — | 2025-07-01 00:00:00 | D |
| 9 | 5000 | nan | — | — | CHUNG KEVIN | Officer | — | 2025-07-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -23.89M | -19.44M | -11.61M | -4.36M |
| TotalUnusualItems | -697.00K | -5.71M | 50.00K | -27.00K |
| TotalUnusualItemsExcludingGoodwill | -697.00K | -5.71M | 50.00K | -27.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.83M | -26.23M | -12.19M | -4.60M |
| ReconciledCostOfRevenue | 0.00 | 0.00 | ||
| EBITDA | -24.58M | -25.15M | -11.56M | -4.38M |
| EBIT | -24.58M | -25.15M | -11.56M | -4.38M |
| NetInterestIncome | -143.00K | -1.08M | -630.00K | -212.00K |
| InterestExpense | 244.00K | 1.08M | 630.00K | 212.00K |
| InterestIncome | 101.00K | 0.00 | ||
| NormalizedIncome | -24.13M | -20.52M | -12.24M | -4.57M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.83M | -26.23M | -12.19M | -4.60M |
| TotalExpenses | 17.98M | 14.21M | 11.61M | 4.45M |
| TotalOperatingIncomeAsReported | -17.84M | -14.21M | -11.61M | -4.45M |
| DilutedAverageShares | 374.36K | 86.68K | 32.84K | 50.80K |
| BasicAverageShares | 374.36K | 86.68K | 32.84K | 50.80K |
| DilutedEPS | -66.30 | -302.60 | -700.00 | -90.48 |
| BasicEPS | -66.30 | -302.60 | -700.00 | -90.48 |
| DilutedNIAvailtoComStockholders | -24.83M | -26.23M | -12.19M | -4.60M |
| NetIncomeCommonStockholders | -24.83M | -26.23M | -12.19M | -4.60M |
| NetIncome | -24.83M | -26.23M | -12.19M | -4.60M |
| NetIncomeIncludingNoncontrollingInterests | -24.83M | -26.23M | -12.19M | -4.60M |
| NetIncomeContinuousOperations | -24.83M | -26.23M | -12.19M | -4.60M |
| TaxProvision | 3.00K | 0.00 | 1.00K | -1.00K |
| PretaxIncome | -24.83M | -26.23M | -12.19M | -4.60M |
| OtherIncomeExpense | -6.84M | -10.94M | 50.00K | 64.00K |
| OtherNonOperatingIncomeExpenses | -6.14M | -5.23M | 91.00K | |
| SpecialIncomeCharges | 0.00 | -4.95M | 0.00 | 0.00 |
| GainOnSaleOfPPE | 0.00 | |||
| OtherSpecialCharges | 4.95M | |||
| GainOnSaleOfSecurity | -697.00K | -763.00K | 50.00K | -27.00K |
| NetNonOperatingInterestIncomeExpense | -143.00K | -1.08M | -630.00K | -212.00K |
| InterestExpenseNonOperating | 244.00K | 1.08M | 630.00K | 212.00K |
| InterestIncomeNonOperating | 101.00K | 0.00 | ||
| OperatingIncome | -17.84M | -14.21M | -11.61M | -4.45M |
| OperatingExpense | 17.98M | 14.21M | 11.61M | 4.45M |
| OtherOperatingExpenses | 2.19M | |||
| ResearchAndDevelopment | 9.11M | 5.97M | 2.50M | 2.77M |
| SellingGeneralAndAdministration | 8.87M | 8.24M | 6.92M | 1.68M |
| GeneralAndAdministrativeExpense | 8.87M | 8.24M | 6.92M | 1.68M |
| OtherGandA | 8.87M | 8.24M | 6.92M | 1.68M |
| GrossProfit | 135.00K | 0.00 | ||
| CostOfRevenue | 0.00 | 0.00 | ||
| TotalRevenue | 135.00K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 135.00K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 597.72K | 190.46K | 50.80K | 50.80K |
| ShareIssued | 597.72K | 190.46K | 50.80K | 50.80K |
| NetDebt | 8.90M | 8.78M | 2.11M | |
| TotalDebt | 574.00K | 9.08M | 8.83M | 2.62M |
| TangibleBookValue | -2.18M | -13.87M | -20.76M | -2.82M |
| InvestedCapital | -1.61M | -4.79M | -11.93M | -194.00K |
| WorkingCapital | -3.08M | -10.74M | -14.63M | -2.52M |
| NetTangibleAssets | -2.18M | -13.87M | -20.76M | -2.82M |
| CommonStockEquity | -2.18M | -13.87M | -20.76M | -2.82M |
| TotalCapitalization | -2.18M | -9.53M | -13.11M | -2.57M |
| TotalEquityGrossMinorityInterest | -2.18M | -13.87M | -20.76M | -2.82M |
| StockholdersEquity | -2.18M | -13.87M | -20.76M | -2.82M |
| RetainedEarnings | -139.56M | -114.73M | -88.50M | -76.31M |
| AdditionalPaidInCapital | 137.38M | 100.86M | 67.74M | 73.50M |
| CapitalStock | 2.00K | 1.00K | 1.00K | 1.00K |
| CommonStock | 2.00K | 1.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 6.84M | 17.38M | 23.80M | 3.42M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 4.34M | 7.65M | 299.00K |
| PreferredSecuritiesOutsideStockEquity | 73.35M | |||
| DerivativeProductLiabilities | 0.00 | 55.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 4.34M | 7.65M | 244.00K | |
| LongTermDebt | 4.34M | 7.65M | 244.00K | |
| CurrentLiabilities | 6.84M | 13.05M | 16.15M | 3.12M |
| OtherCurrentLiabilities | 33.00K | 2.31M | 10.80M | 471.00K |
| CurrentDeferredLiabilities | 0.00 | 100.00K | ||
| CurrentDeferredRevenue | 0.00 | 100.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 574.00K | 4.74M | 1.18M | 2.38M |
| CurrentDebt | 574.00K | 4.74M | 1.18M | 2.38M |
| OtherCurrentBorrowings | 574.00K | 4.74M | 1.18M | 2.38M |
| CurrentNotesPayable | 1.18M | 0.00 | ||
| PayablesAndAccruedExpenses | 6.23M | 5.89M | 4.17M | 271.00K |
| CurrentAccruedExpenses | 3.19M | 1.52M | 2.25M | 186.00K |
| InterestPayable | 19.00K | 112.00K | 72.00K | |
| Payables | 3.05M | 4.37M | 1.93M | 85.00K |
| AccountsPayable | 3.05M | 4.37M | 1.93M | 85.00K |
| TotalAssets | 4.66M | 3.51M | 3.04M | 603.00K |
| TotalNonCurrentAssets | 892.00K | 1.21M | 1.52M | 2.00K |
| OtherNonCurrentAssets | 892.00K | 1.21M | 1.52M | 2.00K |
| FinancialAssets | 1.73M | 0.00 | ||
| CurrentAssets | 3.77M | 2.31M | 1.52M | 601.00K |
| PrepaidAssets | 1.83M | 2.13M | 1.46M | 33.00K |
| Inventory | 0.00 | |||
| Receivables | 112.00K | 0.00 | 12.00K | 58.00K |
| OtherReceivables | 12.00K | 58.00K | ||
| AccountsReceivable | 112.00K | 0.00 | ||
| AllowanceForDoubtfulAccountsReceivable | 0.00 | |||
| GrossAccountsReceivable | 112.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 1.82M | 176.00K | 47.00K | 510.00K |
| CashAndCashEquivalents | 1.82M | 176.00K | 47.00K | 510.00K |
| CashFinancial | 1.82M | 176.00K | 47.00K | 510.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.01M | -10.29M | -7.79M | -5.11M |
| RepaymentOfDebt | -6.10M | -5.27M | -78.00K | -20.00K |
| IssuanceOfDebt | 1.69M | 8.80M | 3.56M | 2.84M |
| IssuanceOfCapitalStock | 17.44M | 6.61M | 10.00M | 0.00 |
| InterestPaidSupplementalData | 553.00K | 1.13M | 6.00K | 0.00 |
| IncomeTaxPaidSupplementalData | 3.00K | 0.00 | 1.00K | 0.00 |
| EndCashPosition | 1.82M | 176.00K | 47.00K | 510.00K |
| BeginningCashPosition | 176.00K | 47.00K | 510.00K | 2.81M |
| ChangesInCash | 1.64M | 129.00K | -463.00K | -2.30M |
| FinancingCashFlow | 17.65M | 10.41M | 7.33M | 2.82M |
| CashFlowFromContinuingFinancingActivities | 17.65M | 10.41M | 7.33M | 2.82M |
| NetOtherFinancingCharges | -500.00K | -1.21M | ||
| ProceedsFromStockOptionExercised | 4.62M | 772.00K | -4.94M | 0.00 |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 17.44M | 6.61M | 10.00M | 0.00 |
| CommonStockIssuance | 17.44M | 6.61M | 10.00M | 0.00 |
| NetIssuancePaymentsOfDebt | -4.41M | 3.53M | 3.48M | 2.82M |
| NetLongTermDebtIssuance | -4.41M | 3.53M | 3.48M | 2.82M |
| LongTermDebtPayments | -6.10M | -5.27M | -78.00K | -20.00K |
| LongTermDebtIssuance | 1.69M | 8.80M | 3.56M | 2.84M |
| OperatingCashFlow | -16.01M | -10.29M | -7.79M | -5.11M |
| CashFlowFromContinuingOperatingActivities | -16.01M | -10.29M | -7.79M | -5.11M |
| ChangeInWorkingCapital | 992.00K | 2.88M | 2.55M | -680.00K |
| ChangeInOtherCurrentLiabilities | -100.00K | 0.00 | ||
| ChangeInOtherCurrentAssets | 313.00K | 0.00 | 0.00 | |
| ChangeInPayablesAndAccruedExpense | 594.00K | 2.96M | 3.62M | -747.00K |
| ChangeInAccruedExpense | 1.88M | 517.00K | 2.07M | -450.00K |
| ChangeInPayable | -1.28M | 2.44M | 1.55M | -297.00K |
| ChangeInAccountPayable | -1.28M | 2.44M | 1.55M | -297.00K |
| ChangeInPrepaidAssets | 297.00K | -97.00K | -1.07M | 12.00K |
| ChangeInInventory | 0.00 | 55.00K | ||
| ChangeInReceivables | -112.00K | 12.00K | 4.00K | 0.00 |
| ChangesInAccountReceivables | -112.00K | 0.00 | ||
| OtherNonCashItems | 102.00K | 48.00K | 583.00K | 212.00K |
| StockBasedCompensation | 887.00K | 1.93M | 1.31M | 14.00K |
| UnrealizedGainLossOnInvestmentSecurities | 6.14M | 5.38M | 0.00 | |
| OperatingGainsLosses | 697.00K | 5.71M | -50.00K | -64.00K |
| GainLossOnInvestmentSecurities | 697.00K | 763.00K | -50.00K | 27.00K |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -24.83M | -26.23M | -12.19M | -4.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ICU
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|